RBC Capital Reiterates Outperform on aTyr Pharma, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating on aTyr Pharma (NASDAQ:ATYR) and maintained a price target of $16.
August 14, 2024 | 4:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on aTyr Pharma and maintained a price target of $16, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and the maintenance of a $16 price target by RBC Capital suggests strong confidence in aTyr Pharma's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100